Bronfman E.L. Rothschild L.P. lifted its holdings in Amgen Inc. (NASDAQ:AMGN) by 17.3% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,997 shares of the medical research company’s stock after buying an additional 737 shares during the quarter. Bronfman E.L. Rothschild L.P.’s holdings in Amgen were worth $861,000 as of its most recent SEC filing.
Other large investors have also added to or reduced their stakes in the company. TrimTabs Asset Management LLC grew its position in shares of Amgen by 88.9% in the 1st quarter. TrimTabs Asset Management LLC now owns 612 shares of the medical research company’s stock worth $100,000 after buying an additional 288 shares during the period. American Beacon Advisors Inc. purchased a new stake in shares of Amgen in the 1st quarter worth about $106,000. Nelson Roberts Investment Advisors LLC purchased a new stake in shares of Amgen in the 1st quarter worth about $121,000. Grove Bank & Trust grew its position in shares of Amgen by 87.4% in the 2nd quarter. Grove Bank & Trust now owns 731 shares of the medical research company’s stock worth $126,000 after buying an additional 341 shares during the period. Finally, Enterprise Financial Services Corp grew its position in shares of Amgen by 18.0% in the 2nd quarter. Enterprise Financial Services Corp now owns 748 shares of the medical research company’s stock worth $129,000 after buying an additional 114 shares during the period. 78.20% of the stock is currently owned by hedge funds and other institutional investors.
In related news, Director Carbonnel Francois De sold 4,000 shares of the stock in a transaction that occurred on Wednesday, November 8th. The shares were sold at an average price of $173.61, for a total value of $694,440.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Sean E. Harper sold 1,525 shares of the stock in a transaction that occurred on Monday, November 13th. The stock was sold at an average price of $171.58, for a total transaction of $261,659.50. Following the completion of the sale, the executive vice president now directly owns 57,631 shares of the company’s stock, valued at $9,888,326.98. The disclosure for this sale can be found here. Insiders sold a total of 7,050 shares of company stock valued at $1,239,673 over the last three months. 0.19% of the stock is currently owned by insiders.
AMGN has been the topic of a number of analyst reports. Royal Bank Of Canada initiated coverage on shares of Amgen in a research note on Thursday, September 14th. They issued a “sector perform” rating and a $192.00 price target on the stock. Bank of America Corporation upped their price target on shares of Amgen to $210.00 and gave the stock a “buy” rating in a research note on Thursday, October 5th. Cann reiterated a “buy” rating and issued a $203.00 price target on shares of Amgen in a research note on Friday, October 6th. Morgan Stanley reiterated an “overweight” rating and issued a $196.00 price target (up previously from $189.00) on shares of Amgen in a research note on Friday, October 6th. Finally, Mizuho reiterated a “buy” rating and issued a $198.00 price target on shares of Amgen in a research note on Friday, October 6th. Thirteen equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the stock. Amgen currently has a consensus rating of “Buy” and a consensus price target of $190.03.
Shares of Amgen Inc. (AMGN) opened at $170.00 on Friday. The stock has a market cap of $123,404.88, a P/E ratio of 13.51, a P/E/G ratio of 2.46 and a beta of 1.37. Amgen Inc. has a fifty-two week low of $138.83 and a fifty-two week high of $191.10. The company has a quick ratio of 5.72, a current ratio of 6.07 and a debt-to-equity ratio of 1.05.
Amgen (NASDAQ:AMGN) last released its earnings results on Wednesday, October 25th. The medical research company reported $3.27 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $3.11 by $0.16. The company had revenue of $5.77 billion during the quarter, compared to analyst estimates of $5.75 billion. Amgen had a net margin of 35.54% and a return on equity of 29.90%. The firm’s quarterly revenue was down .7% compared to the same quarter last year. During the same period in the prior year, the firm posted $3.02 EPS. analysts predict that Amgen Inc. will post 12.66 earnings per share for the current fiscal year.
Amgen announced that its Board of Directors has initiated a share repurchase plan on Wednesday, October 25th that authorizes the company to buyback $5.00 billion in shares. This buyback authorization authorizes the medical research company to repurchase shares of its stock through open market purchases. Shares buyback plans are generally an indication that the company’s board of directors believes its stock is undervalued.
The company also recently announced a quarterly dividend, which will be paid on Friday, December 8th. Investors of record on Friday, November 17th will be issued a $1.15 dividend. This represents a $4.60 annualized dividend and a yield of 2.71%. The ex-dividend date is Thursday, November 16th. Amgen’s dividend payout ratio is 41.63%.
TRADEMARK VIOLATION NOTICE: This piece of content was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece of content on another site, it was stolen and republished in violation of U.S. and international copyright legislation. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2017/11/19/bronfman-e-l-rothschild-l-p-acquires-737-shares-of-amgen-inc-amgn.html.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.